MHC class I-related chain a conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7516-7522

  Germain, Claire ^a   Larbouret, Christel ^a   Cesson, Valérie ^b   Donda, Alena ^b   Held, Werner ^b   Mach, Jean Pierre ^b   Pèlegrin, André ^a   Robert, Bruno ^a  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CD20 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; RECOMBINANT ANTIGEN; TUMOR ANTIGEN;

ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; FAST PROTEIN LIQUID CHROMATOGRAPHY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TUMOR CELL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CELL LINE; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 27144533951     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0872     Document Type: Article

References (40)

1. Mach J-P, Buchegger F, Forni M, et al. Use of radio-labelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photo-scanning and tomoscintigraphy. Immunol Today 1981;2:239-49.
2. Aboud-Pirak E, Hurwitz E, Bellot F, Schlessinger J, SeIa M. Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor. Proc Natl Acad Sci U S A 1989;86:3778-81.
3. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.
4. Robert B, Guillaume P, Luescher I, Romero P, Mach JP. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol 2000;30:3165-70.
5. Robert B, Guillaume P, Luescher I, et al. Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide coupled to antibody fragments. Cancer Immun 2001;1:2.
6. Ogg GS, Dunbar PR, Cerundolo V, McMichael AJ, Lemoine NR, Savage P. Sensitization of turnout cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer 2000;82:1058-62.
7. Lev A, Novak H, Segal D, Reiter Y. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes. J Immunol 2002;169:2988-96.
8. Donda A, Cesson V, Mach JP, Corradin G, Primus FJ, Robert B. In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts. Cancer Immun 2003;14:3-11.
9. Lev A, Noy R, Oved K, et al. Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci U S A 2004;101:9051-6.
10. Strong RK. Asymmetric ligand recognition by the activating natural killer cell receptor NKG2D, a symmetric homodimer. Mol Immunol 2001;38:1029-37.
11. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A 1996;93:12445-50.
12. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 1998;279:1737-40.
13. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178-86.
14. Robinson J, Perez-Rodriguez M, Waller MJ, et al. MICA sequences 2000. Immunogenetics 2001;53:150-69.
15. Zhang Y, Lazaro AM, Lavingia B, Stastny P. Typing for all known MICA alleles by group-specific PCR and SSOP Hum Immunol 2000;62:620-31.
16. Katsuyama Y, Ota M, Ando H, et al. Sequencing based typing for genetic polymorphisms in exons, 2, 3 and 4 of the MICA gene. Tissue Antigens 1999;54:178-84.
17. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9.
18. Wu J, Song Y, Bakker AB, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999;285:730-2.
19. Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003;63:8996-9006.
20. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001;2:255-60.
21. Basse PH, Whiteside TL, Chambers W, Herberman RB. Therapeutic activity of NK cells against tumors, Int Rev Immunol 2001;20:439-501.
22. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
23. Salih HR, Rammensee H-G, Steinte A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-102.
24. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
25. Vetter CS, Lieb W, Bröcker E-B, Becker JC. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br J Cancer 2004;91:1495-9.
26. Clarke P, Mann J, Simpson JF, Rickard-Dickinson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 1998;58:1469-77.
27. Corbett TH, Griswold DPJ, Roberts BJ, Peckham JC, Schabel FMJ. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975;35:2434-9.
28. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterisation of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996;24:406-15.
29. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994;8:652-8.
30. Schneider P. Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol 2000;322:325-45.
31. Buchegger F, Haskell CM, Schreyer M, et al. Radio-labeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med 1983;158:413-27.
32. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
33. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
34. Tieng V, Le Bouguenec C, Du Merle L, et al. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci U S A 2002;99:2977-82.
35. Buchegger F, Haskell CM, Schreyer M, et al. Radio-labeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med 1983;158:413-27.
36. McCall AM, Shahied L, Amoroso AR, et al. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001;166:6112-7.
37. Steinle A, Li P, Morris DL, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 2001;53:279-87.
38. Salirt HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-96.
39. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004;114:560-8.
40. Hanna J, Gonen-Gross T, Fitchett J, et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest 2004;114:1612-23.